Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Jacobson, Blake A ^a   Thumma, Saritha C ^a   Jay Dixon, Joseph ^a   Patel, Manish R ^a   Dubear Kroening, K ^b   Kratzke, Marian G ^c   Etchison, Ryan G ^a   Konicek, Bruce W ^d   Graff, Jeremy R ^d   Kratzke, Robert A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b University of Wisconsin Fox Valley   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DEOXYCYTIDINE; GEMCITABINE; GLUTAMIC ACID DERIVATIVE; GUANINE; INITIATION FACTOR 4E; INITIATION FACTOR 4F; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORNITHINE DECARBOXYLASE; PEMETREXED; PROTEIN BCL 2; PROTEIN BINDING;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL COUNT; DRUG EFFECTS; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HUMAN; MESOTHELIOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ACTINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL COUNT; CELL LINE, TUMOR; DEOXYCYTIDINE; EUKARYOTIC INITIATION FACTOR-4E; EUKARYOTIC INITIATION FACTOR-4F; GENE EXPRESSION; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES, ANTISENSE; ORNITHINE DECARBOXYLASE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TRANSFECTION;

EID: 84894136566     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081669     Document Type: Article

References (46)

1. Britton M (2002) The epidemiology of mesothelioma. Semin Oncol 29: 18-25. doi:10.1053/sonc.2002.33078. PubMed: 11836665.
2. Carbone M, Albelda SM, Broaddus VC, Flores RM, Hillerdal G et al. (2007) Eighth international mesothelioma interest group. Oncogene 26: 6959-6967. doi:10.1038/sj.onc.1210515. PubMed: 17496929. (Pubitemid 350014615)
3. Hiremath LS, Webb NR, Rhoads RE (1985) Immunological detection of the messenger RNA cap-binding protein. J Biol Chem 260: 7843-7849. PubMed: 3891747. (Pubitemid 15228219)
4. Duncan R, Milburn SC, Hershey JW (1987) Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J Biol Chem 262: 380-388. PubMed: 3793730. (Pubitemid 17000032)
5. Silvera D, Formenti SC, Schneider RJ (2010) Translational control in cancer. Nat Rev Cancer 10: 254-266. doi:10.1038/nrc2824. PubMed: 20332778.
6. Thumma SC, Kratzke RA (2007) Translational control: a target for cancer therapy. Cancer Lett 258: 1-8. doi:10.1016/j.canlet.2007.08.022. PubMed: 17923280. (Pubitemid 47600498)
7. Sonenberg N, Hinnebusch AG (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136: 731-745. doi:10.1016/j.cell.2009.01.042. PubMed: 19239892.
8. Hsieh AC, Ruggero D (2010) Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res 16: 4914-4920. doi: 10.1158/1078-0432.CCR-10-0433. PubMed: 20702611.
9. Polunovsky VA, Bitterman PB (2006) The cap-dependent translation apparatus integrates and amplifies cancer pathways. RNA Biol 3: 10-17. doi:10.4161/rna.3.1.2718. PubMed: 17114939.
10. Lazaris-Karatzas A, Montine KS, Sonenberg N (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345: 544-547. doi:10.1038/345544a0. PubMed: 2348862.
11. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M et al. (2004) Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5: 553-563. doi:10.1016/j.ccr.2004.05.024. PubMed: 15193258. (Pubitemid 38748917)
12. Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS et al. (2009) eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 69: 3866-3873. doi:10.1158/0008-5472.CAN-08-3472. PubMed: 19383915.
13. Jacobson BA, Alter MD, Kratzke MG, Frizelle SP, Zhang Y et al. (2006) Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res 66: 4256-4262. doi:10.1158/0008-5472.CAN-05-2879. PubMed: 16618749.
14. Coleman LJ, Peter MB, Teall TJ, Brannan RA, Hanby AM et al. (2009) Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 100: 1393-1399. doi:10.1038/sj.bjc.6605044. PubMed: 19367274.
15. Chen CN, Hsieh FJ, Cheng YM, Lee PH, Chang KJ (2004) Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J Surg Oncol 86: 22-27. doi:10.1002/jso.20037. PubMed: 15048676.
16. Rosenwald IB, Chen JJ, Wang S, Savas L, London IM et al. (1999) Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 18: 2507-2517. doi: 10.1038/sj.onc. 1202563. PubMed: 10229202. (Pubitemid 29206164)
17. Salehi Z, Mashayekhi F, Shahosseini F (2007) Significance of eIF4E expression in skin squamous cell carcinoma. Cell Biol Int 31: 1400-1404. doi:10.1016/j.cellbi.2007.06.006. PubMed: 17689990. (Pubitemid 47371096)
18. Wang S, Rosenwald IB, Hutzler MJ, Pihan GA, Savas L et al. (1999) Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. Am J Pathol 155: 247-255. doi:10.1016/S0002-9440(10) 65118-8. PubMed: 10393856. (Pubitemid 29318722)
19. Patel MR, Jacobson BA, De A, Frizelle SP, Janne P et al. (2007) Ras pathway activation in malignant mesothelioma. J Thorac Oncol 2: 789-795. doi:10.1097/JTO.0b013e31811f3aab. PubMed: 17805054. (Pubitemid 47361018)
20. Jacobson BA, De A, Kratzke MG, Patel MR, Jay-Dixon J et al. (2009) Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma. Br J Cancer 101: 424-431. doi:10.1038/sj.bjc. 6605184. PubMed: 19603014.
21. DeFatta RJ, Nathan CA, De Benedetti A (2000) Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 110: 928-933. doi: 10.1097/00005537-200006000-00007. PubMed: 10852506. (Pubitemid 30368633)
22. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y et al. (2008) eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7: 1782-1788. doi: 10.1158/1535-7163.MCT-07-2357. PubMed: 18644990.
23. Herbert TP, Fåhraeus R, Prescott A, Lane DP, Proud CG (2000) Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Curr Biol 10: 793-796. doi:10.1016/S0960-9822(00)00567-4. PubMed: 10898981. (Pubitemid 30466944)
24. Ko SY, Guo H, Barengo N, Naora H (2009) Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Cancer Res 15: 4336-4347. doi: 10.1158/1078-0432.CCR-08-2924. PubMed: 19458052.
25. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY et al. (2007) Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128: 257-267. doi:10.1016/j.cell.2006.11.046. PubMed: 17254965. (Pubitemid 46137991)
26. Cencic R, Hall DR, Robert F, Du Y, Min J et al. (2010) Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A 108: 1046-1051. PubMed: 21191102.
27. Jia Y, Chiu TL, Amin EA, Polunovsky V, Bitterman PB et al. (2010) Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP. Eur J Med Chem 45: 1304-1313. doi:10.1016/j.ejmech.2009.11. 054. PubMed: 20060622.
28. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D et al. (2007) Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117: 2638-2648. doi:10.1172/JCI32044. PubMed: 17786246. (Pubitemid 47494364)
29. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A et al. (2011) A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 17: 6582-6591. doi: 10.1158/1078-0432.CCR-11-0430. PubMed: 21831956.
30. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446. doi:10.1158/1538-7445. AM10-440. PubMed: 20068163.
31. Nestle FO, Mitra RS, Bennett CF, Chan H, Nickoloff BJ (1994) Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol 103: 569-575. doi:10.1111/1523-1747.ep12396876. PubMed: 7930684. doi:10.1111/1523-1747.ep12396876 PubMed: 7930684
32. Conrad AH, Behlke MA, Jaffredo T, Conrad GW (1998) Optimal lipofection reagent varies with the molecular modifications of the DNA. Antisense Nucleic Acid Drug Dev 8: 427-434. doi:10.1089/oli. 1.1998.8.427. PubMed: 9826269.
33. Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD et al. (1995) Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 59: 835-844. doi:10.1016/0003-4975(95)00045-M. PubMed: 7695406.
34. De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199. doi:10.1038/sj.onc.1207545. PubMed: 15094768. (Pubitemid 38638830)
35. Larsson O, Perlman DM, Fan D, Reilly CS, Peterson M et al. (2006) Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res 34: 4375-4386. doi:10.1093/nar/gkl558. PubMed: 16936314. (Pubitemid 44567037)
36. Li S, Perlman DM, Peterson MS, Burrichter D, Avdulov S et al. (2004) Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis. J Biol Chem 279: 21312-21317. doi:10.1074/jbc.M312467200. PubMed: 14990584. (Pubitemid 38656538)
37. Li S, Takasu T, Perlman DM, Peterson MS, Burrichter D et al. (2003) Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 278: 3015-3022. doi: 10.1074/jbc.M208821200. PubMed: 12441348. (Pubitemid 36801209)
38. Polunovsky VA, Rosenwald IB, Tan AT, White J, Chiang L et al. (1996) Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 16: 6573-6581. PubMed: 8887686. (Pubitemid 26361016)
39. Cencic R, Carrier M, Trnkus A, Porco JA Jr., Minden M et al. (2009) Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res 34: 535-541. PubMed: 19726085.
40. Dong K, Wang R, Wang X, Lin F, Shen JJ et al. (2009) Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat 113: 443-456. doi:10.1007/s10549-008-9956-x. PubMed: 18327707.
41. Graff JR, Zimmer SG (2003) Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 20: 265-273. doi:10.1023/A:1022943419011. PubMed: 12741684. (Pubitemid 36513230)
42. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW et al. (2004) eIF4E - from translation to transformation. Oncogene 23: 3172-3179. doi:10.1038/sj.onc. 1207549. PubMed: 15094766.
43. Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G (2007) Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res 67: 289-299. doi:10.1158/0008-5472.CAN-05- 4623. PubMed: 17210710. (Pubitemid 46142787)
44. Ruggero D, Montanaro L, Ma L, Xu W, Londei P et al. (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10: 484-486. doi:10.1038/nm1042. PubMed: 15098029. (Pubitemid 38667906)
45. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S et al. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337. doi:10.1038/nature02369. PubMed: 15029198. (Pubitemid 38418805)
46. Hayman TJ, Williams ES, Jamal M, Shankavaram UT, Camphausen K et al. (2012) Translation Initiation Factor eIF4E Is a Target for Tumor Cell Radiosensitization. Cancer Res 72: 2362-2372. doi: 10.1158/1538-7445.AM2012- 2362. PubMed: 22397984.